Invention Grant
- Patent Title: Therapeutic peptides that target TGF-beta interaction
-
Application No.: US16477423Application Date: 2018-01-12
-
Publication No.: US11406665B2Publication Date: 2022-08-09
- Inventor: Johan Erik Simon Fredriksson , Olof Andries Blokzijl
- Applicant: GENAGON THERAPEUTICS AB
- Applicant Address: SE Solna
- Assignee: GENAGON THERAPEUTICS AB
- Current Assignee: GENAGON THERAPEUTICS AB
- Current Assignee Address: SE Solna
- Agency: Porter Wright Morris & Arthur LLP
- Priority: GB1700567 20170112
- International Application: PCT/EP2018/050776 WO 20180112
- International Announcement: WO2018/130659 WO 20180719
- Main IPC: A61K35/17
- IPC: A61K35/17 ; C07K14/495 ; C07K14/71 ; A61K38/00
Abstract:
The invention relates to apolypeptide capable of binding to TGF-β for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-β, wherein said polypeptide is capable of inhibiting the interaction of TGF-β with the receptor CLPTM1.
Public/Granted literature
- US20190328788A1 THERAPEUTIC PEPTIDES THAT TARGET TGF-BETA INTERACTION Public/Granted day:2019-10-31
Information query
IPC分类:
